Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).

Transplant Cell Ther · 2022 · PMC9464362 · PMID 36103987

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Data from the multinational, randomized, placebo-controlled ACTT-1 clinical trial of hospitalized patients (n =1062) with COVID-19 showed that those who received RDV had a significant reduction in time to clinical recovery compared with the placebo group (11 days versus 15 days) and a nonsignificant trend toward lower mortality (8% versus 11.6%) [49] .

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.